Roche Holding AG Net Cash Flow 2012-2025 | RHHBY
Roche Holding AG annual/quarterly net cash flow history and growth rate from 2012 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
- Roche Holding AG net cash flow for the quarter ending December 31, 2025 was $-1.681B, a 18.92% increase year-over-year.
- Roche Holding AG net cash flow for the twelve months ending December 31, 2025 was $-0.047B, a 99.02% decline year-over-year.
- Roche Holding AG annual net cash flow for 2025 was $-1.681B, a 192.57% decline from 2024.
- Roche Holding AG annual net cash flow for 2024 was $1.816B, a 323.53% increase from 2023.
- Roche Holding AG annual net cash flow for 2023 was $0.429B, a 122.01% decline from 2022.
|
Roche Holding AG Annual Net Cash Flow (Millions of US $) |
|
|---|---|
| 2025 | $-1,681 |
| 2024 | $1,816 |
| 2023 | $429 |
| 2022 | $-1,948 |
| 2021 | $1,229 |
| 2020 | $-371 |
| 2019 | $-610 |
| 2018 | $2,006 |
| 2017 | $565 |
| 2016 | $439 |
| 2015 | $-11 |
| 2014 | $-282 |
| 2013 | $-572 |
| 2012 | $721 |
| 2011 | $2,279 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $318.782B | $76.450B |
| Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |